T-cell therapy unlocks the power of the immune system by re-programming T cells to detect and eliminate cancer cells. The potential of this approach remains largely untapped, however, due to the lack of identified targets.

We are addressing this challenge using our proprietary genome-wide, high-throughput platform to identify the natural targets of anti-tumor T cells residing in the tumors of cancer patients. When we identify a novel target, we simultaneously identify a T cell receptor (TCR) that recognizes that target and can potentially be used in safe and effective TCR T-cell therapy.

PATIENT TUMORS CONTAIN TCRs WITH THE POTENTIAL TO CURE